Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02743819
Title Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of South Alabama Mobile Alabama 36604 United States Details
Mount Sinai Medical Center of Florida Miami Beach Florida 33140 United States Details
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Decatur Memorial Hospital Decatur Illinois 62526 United States Details
NorthShore University HealthSystem Evanston Illinois 60201 United States Details
Oncology Specialists S.C. Park Ridge Illinois 60068 United States Details
Illinois Cancer Care Peoria Illinois 61615 United States Details
Fort Wayne Medical Oncology and Hematology, Inc. Fort Wayne Indiana 46804 United States Details
Virginia Commonwealth University/ Massey Cancer Center Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field